5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A clinical overview of tesamorelin (Egrifta) compounding legality, FDA approval history, shortage designations, and what patients and providers need to know about access in 2026.
A detailed review of Egrifta (tesamorelin) FAERS adverse event reports, FDA label warnings, post-market surveillance data, and clinical trial safety findings for patients and clinicians.
A detailed review of FDA label changes for Egrifta and Egrifta SV (tesamorelin) from 2020 through 2026, including updated warnings, post-marketing safety data, and clinical guidance, with sourcing notes on where a claim still needs independent verification.
A comprehensive review of Egrifta (tesamorelin) regulatory history, patent disputes, FDA labeling requirements, and post-market safety surveillance, with primary-source citations throughout.
A comprehensive review of tesamorelin's FDA approval history, prescribing label, post-market safety data, pipeline extensions, and emerging GHRH-analog research, prepared by the HealthRX.com Editorial Team.